OsteoporeASX:OSX -11.11% EPS without NRI is A$-0.02 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 666 Medical Devices & Instruments companies, Osteopore ranks better than 84.08% on this metric.
Osteopore's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was A$-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 39.40% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Osteopore's EPS without NRI or its related term are showing as below:
ASX:OSX'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.5 Med: 22.75 Max: 39.4
Current: 39.4
During the past 8 years, Osteopore's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 39.40% per year. The lowest was -20.50% per year. And the median was 22.75% per year.
ASX:OSX's 3-Year EPS without NRI Growth Rate is ranked better than 84.08% of 666
companies
in the Medical Devices & Instruments industry
Industry Median: 8.15
vs ASX:OSX: 39.40
Osteopore's EPS (Diluted) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
Osteopore's EPS (Basic) for the
six
months ended in Dec. 2025 was A$-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.02.
Osteopore (ASX:OSX) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Osteopore EPS without NRI Related Terms
Osteopore EPS without NRI Historical Data
* Premium members only.
The historical data trend for Osteopore's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSX vs ISRG, BDX, MDLN: EPS without NRI Comparison
For the Medical Instruments & Supplies subindustry, Osteopore's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Osteopore PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Osteopore's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Osteopore's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Osteopore (ASX:OSX) has a EPS without NRI of A$-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Osteopore and its competitors. According to the industry distribution chart, Osteopore ranks #106 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 15.9%.
Is Osteopore's EPS without NRI too high?
Osteopore's current EPS without NRI is A$-0.02. Based on the distribution chart, Osteopore ranks #106 out of 666 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Osteopore's EPS without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Osteopore ranks #106 out of 666 companies for EPS without NRI. This places Osteopore in the top 16% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Osteopore and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Osteopore's current EPS without NRI is A$-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Osteopore stock overvalued right now?
Based on GuruFocus' analysis, Osteopore (ASX:OSX) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current EPS without NRI is A$-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Osteopore (ASX:OSX), the current EPS without NRI is A$-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Osteopore Ltd is engaged in the production of 3D-printed bioresorbable implants that are used in conjunction with surgical procedures to assist bone healing. Its products include Osteoplug, which is a bioresorbable implant used for covering trephination burr holes in neurosurgery, and Osteomesh which is a bioresorbable implant used in craniofacial surgery. It operate in the high-growth regenerative medicine sector, where adoption continues to rise as healthcare systems increasingly embrace developed tissue-regenerative solutions. Business operating segments are based on the firm's geographical presence in Singapore and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSX has been successfully added to your 